SEC Form DFiling only, no announcement found
Precision Neuroscience, based in New York, NY, reported $249,999,984 sold in a private offering of equity and options or warrants, with the first sale on September 11, 2026, in a Form D filed with the SEC on September 28, 2026. The filing says 46 investors have already invested. The total offering is stated as Indefinite.
Legal name on the filing: Precision Neuroscience Corp.
| Amount sold | $249,999,984Basis: Form D total amount sold, as of the filing of September 28, 2026. Not the announced round size. |
|---|---|
| Total offering | IndefiniteThe most the company may sell under this offering. Not money raised. |
| Securities offered | Equity; Option, warrant or other right to acquire another security |
| Exemption claimed | Rule 506(b) |
| Date of first sale | September 11, 2026 |
| Investors already invested | 46 |
| Non-accredited investors | None |
| Minimum investment accepted | $0 |
| Part of a merger or acquisition | No |
| Industry group | Other Health Care |
| Principal place of business | New York, NY |
| Jurisdiction of incorporation | DELAWARE |
| Entity type | Corporation |
| Year of incorporation | over five years ago |
| Revenue range | Decline to Disclose |
| SEC CIK | 1858288 |
Round name, valuation, lead investor and participants are not on a Form D, so they are not shown. They appear here only when a press or company announcement is matched to this deal.
| Name, as filed | Relationship | VC Beast profile |
|---|---|---|
| Michael Mager | Executive Officer, DirectorChief Executive Officer | None linked |
| Konstantinos Alataris | Executive Officer, DirectorPresident | None linked |
| Craig Mermel | Executive Officer, DirectorChief AI and Data Officer | None linked |
| Benjamin Rapoport | Executive Officer, DirectorChief Science Officer | None linked |
| Ravi Mehta | Director | None linked |
| Howard Morgan | Director | None linked |
| Michael Kaswan | Executive OfficerChief Financial Officer | None linked |
| Michael Goller | Director | None linked |
| Stephen Biggar | Director | None linked |
Form D lists the company's executive officers, directors and promoters. A director is often an investor's board representative, but the filing does not say who invested.
| Filed | Form | Amount sold | Total offering |
|---|---|---|---|
| Sep 28, 2026 | D (original) | $249,999,984 | Indefinite |
The latest filing states the current amount sold; an amendment replaces the figure before it.
From the issuer's EDGAR filing history. Amounts are shown for filings in our warehouse, which holds operating-company filings from July 16, 2026.
Filing only, no announcement found. The only source for this deal is the company's own SEC filing, made under penalty of law. When a press or company announcement is matched to it, it is cited here with the round name it gives.
Amount sold is the filing's total amount sold; total offering is its authorized maximum. This page was built from filings received through September 29, 2026. Report an error on the corrections page.
Cite this deal
VC Beast, "Precision Neuroscience: SEC Form D deal record", https://vcbeast.com/deals/precision-neuroscience-form-d-2026-09-11. Source: SEC EDGAR, accession 0001123292-26-001327.